Improving the Diagnosis and Treatment of Castleman Disease: Expert Insights



Release Date: February 9, 2022 
Expiration Date: February 9, 2023
Time to Complete Activity:  1.0 hour


Faculty Co-Chairs

David C. Fajgenbaum, MD, MBA, MSc 

Assistant Professor of Medicine
Division of Translational Medicine and Human Genetics 
University of Pennsylvania 
Associate Director, Patient Impact
Penn Orphan Disease Center 
Founding Director
Center for Cytokine Storm Treatment and Laboratory
Co-Founder and Executive Director
Castleman Disease Collaborative Network
Philadelphia, PA

Sudipto Mukherjee, MD, PhD, MPH
Assistant Professor of Medicine 
Lerner College of Medicine at CWRU
Director of Rare Cancers and Blood Diseases Program
Department of Hematology and Medical Oncology
Leukemia Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH
This activity is provided by Paradigm Medical Communications, LLC.   

In collaboration with the Castleman Disease Collaborative Network. 

Supporter Acknowledgment
This activity is supported by an educational grant from EUSA Pharma (US) LLC.    

Target Audience
This activity has been designed to address the educational needs of community and academic physicians specializing in hematology and hematology/oncology. It will also benefit other clinicians who manage patients with Castleman disease (CD).

Statement of Need
CD is a rare group of heterogeneous lymphoproliferative disorders, many of which have unknown underlying etiologies. Therefore, hematology/oncology clinicians frequently find the diagnosis and treatment of the disease to be particularly challenging, potentially resulting in delayed diagnosis or misdiagnosis, and/or inappropriate treatment selection. Guidelines for both the diagnosis and treatment of CD are now available, which can guide clinicians through the appropriate steps to improve the care of patients with CD. This program will review key factors for the diagnosis of CD subtypes and will use real-world cases to illustrate the optimal first- and second-line treatment for idiopathic multicentric CD.

Learning Objectives
Upon completion of this activity, participants should be able to:
  • Identify patients with CD
  • Determine evidence-based treatment for CD in alignment with current guidelines

Agenda
Introduction to CD—David C. Fajgenbaum, MD, MBA, MSc 
Diagnosis of CD—David C. Fajgenbaum, MD, MBA, MSc 
Faculty Panel Discussion: Reflection on Experiences With Diagnosis of CD
Treatment of CD—Sudipto Mukherjee, MD, PhD, MPH
Faculty Panel Discussion: Reflection on Experiences With Treatment of iMCD
Conclusions—Sudipto Mukherjee, MD, PhD, MPH
Faculty Discussion

Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

European Accreditation 
Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credits™ to an equivalent number of European CME Credits® (ECMEC®s). Information on the process of converting AMA PRA Category 1 Credits™ to ECMEC®s can be found at: www.eaccme.eu.


PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Instructions for Participation 
To receive a CME certificate of participation, you must:
  • Follow instructions to register or log in with your professional information and complete the preactivity assessment
  • View the online activity in its entirety
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or cme@paradigmmc.com.

There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support: If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.

Disclosure of Relevant Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated. 


David Fajgenbaum, MD, MBA, MSc
Research Funding: EUSA Pharma

Sudipto Mukherjee, MD, PhD, MPH
Advisor: Abbvie Inc; Blueprint Medicines Corporation; Bristol-Myers Squibb Company; Celgene Corporation; EUSA Pharma; Genentech, Inc.; Novartis
Consultant: Bristol-Myers Squibb Company; Celgene Corporation; Novartis
Speakers’ Bureau: EUSA Pharma; Novartis
Research Funding: Bristol-Myers Squibb Company; Jazz Pharmaceuticals, Inc; Novartis
Other: Bristol-Myers Squibb Company (Honoraria)

Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.

Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.


Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. 

Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com

© 2022 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.